Literature DB >> 23598981

Targeting bone physiology for the treatment of metastatic prostate cancer.

Karen A Autio1, Michael J Morris.   

Abstract

Metastatic prostate cancer has a unique predilection for bone that can lead to significant clinical sequelae, such as fracture and cord compression. This tropism for bone yields not only clinical challenges, but also opportunities to understand the tumor biology in bone and to develop relevant therapeutic strategies. The process by which tumor cells migrate to bone, remain dormant, and then colonize and expand is based on complex interactions between prostate cancer tumor cells and the host microenvironment. This review will provide an overview of these interactions as well as therapies targeting osseous metastases in castration-resistant prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23598981      PMCID： PMC3938391     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


  85 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 3.  A perspective on cancer cell metastasis.

Authors:  Christine L Chaffer; Robert A Weinberg
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

4.  Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer.

Authors:  Christel van den Hoogen; Geertje van der Horst; Henry Cheung; Jeroen T Buijs; Rob C M Pelger; Gabri van der Pluijm
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

Review 5.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Authors:  Roopali Roy; Jiang Yang; Marsha A Moses
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

6.  Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells.

Authors:  J L Sanders; N Chattopadhyay; O Kifor; T Yamaguchi; E M Brown
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-12       Impact factor: 4.310

7.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

8.  Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.

Authors:  Linda W Chan; Marsha A Moses; Elizabeth Goley; Mary Sproull; Thierry Muanza; C Norman Coleman; William D Figg; Paul S Albert; Cynthia Ménard; Kevin Camphausen
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

9.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Authors:  Jeffrey A Nemeth; Michael L Cher; Zhao Zhou; Chadwick Mullins; Sunita Bhagat; Mohit Trikha
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150
View more
  5 in total

1.  Osteoclast derivation from mouse bone marrow.

Authors:  Ruth Tevlin; Adrian McArdle; Charles K F Chan; John Pluvinage; Graham G Walmsley; Taylor Wearda; Owen Marecic; Michael S Hu; Kevin J Paik; Kshemendra Senarath-Yapa; David A Atashroo; Elizabeth R Zielins; Derrick C Wan; Irving L Weissman; Michael T Longaker
Journal:  J Vis Exp       Date:  2014-11-06       Impact factor: 1.355

Review 2.  The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.

Authors:  Christina J Turner; Claire M Edwards
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 3.  Primary and Metastatic Bone Tumors of the Patella: Literature Review and Institutional Experience.

Authors:  Nelson Merchán; Caleb M Yeung; Jayden Garcia; Joseph H Schwab; Kevin A Raskin; Erik T Newman; Santiago A Lozano-Calderón
Journal:  Arch Bone Jt Surg       Date:  2022-02

Review 4.  Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.

Authors:  Andrew S Gdowski; Amalendu Ranjan; Jamboor K Vishwanatha
Journal:  J Exp Clin Cancer Res       Date:  2017-08-11

5.  Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases.

Authors:  Bo Peng; Cheng Yang; Jian He
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.